What is the name of your organization?
Vyuhaa Med Data Private Limited
What is the name of your solution?
EDGE-based AI screening system
Provide a one-line summary or tagline for your solution.
EDGE-based Multi-Disease Screening System for resource constrained settings
In what city, town, or region is your solution team headquartered?
India
In what country is your solution team headquartered?
IND
What type of organization is your solution team?
Hybrid of for-profit and nonprofit
Film your elevator pitch.
What specific problem are you solving?
We have developed an EDGE-based multi-disease screening system that enables real-time, AI-assisted diagnostics at the point of care, addressing critical gaps in early detection and accessibility for life-threatening diseases. Traditional screening methods for diseases like cervical cancer, leprosy, and tuberculosis are slow, expensive, and require centralized infrastructure, limiting access in remote and underserved areas.
The flagship product of our system is CerviAI, our AI-powered digital cytology solution for cervical cancer screening. Cervical cancer is the fourth most common cancer in women worldwide, with over 600,000 new cases and 342,000 deaths annually. In India alone, it accounts for 25% of global cervical cancer deaths, primarily due to limited screening coverage and delays in diagnosis. Manual cytology interpretation is labor-intensive and error-prone, leading to missed early-stage cases.
By integrating AI-driven triaging and whole-slide digitization, CerviAI improves speed, accuracy, and scalability, reducing diagnostic workload by 60% and enhancing accessibility for underserved populations. Our solution aligns with WHO’s goal to eliminate cervical cancer by 2030, while our broader EDGE platform paves the way for AI-powered, decentralized diagnostics across multiple diseases.
What is your solution?
Our solution is an EDGE-based multi-disease screening system that enables AI-powered, real-time diagnostics at the point of care. It is designed to screen for diseases like cervical cancer, leprosy, and tuberculosis without relying on centralized labs, making early detection more accessible and efficient.
Our flagship AI product is CerviAI, our AI-driven digital cytology solution for cervical cancer screening. It works by digitizing microscopic slides of cervical samples and using AI algorithms to analyze and classify abnormal cells with high accuracy. This significantly reduces the burden on pathologists by automating preliminary screening and triaging.
Our EDGE platform integrates high-performance computing, whole-slide imaging, and AI models, which can filter out 80-90% of the true negative cases, allowing healthcare providers to perform screenings in real-time, even in remote settings. We are therefore able to create modular and compact lab in-situ which can be used in a mobile setting with or without internet. The system can be deployed in primary health centers, mobile clinics, and hospitals, ensuring faster results, reduced diagnostic errors, and increased screening coverage.
Who does your solution serve, and in what ways will the solution impact their lives?
Our solution serves women in low-resource settings, particularly those in rural and semi-urban areas, who have limited access to cancer screening and diagnostic facilities. Cancers affect women disproportionately and remain leading causes of death among women, yet over 85% of cases occur in low- and middle-income countries (LMICs) due to a lack of early detection and timely intervention.
Currently, women in underserved areas face long wait times, high costs, and logistical barriers in accessing screening programs. Many rely on overburdened healthcare systems, where trained pathologists and diagnostic infrastructure are scarce.
CerviAI, brings AI-powered diagnostics directly to primary health centers and mobile clinics, eliminating the need for centralized labs. By reducing screening costs, increasing speed, and improving accuracy, our solution enables earlier detection, faster treatment, and better health outcomes.
